Receive funding for your R&D Projects!
Your partner for subsidy advice
Your partner for subsidy advice
In chronic myelogenous leukaemia (CML), too many stem cells in the bone marrow are transformed into a type of white blood cell called granulocytes, making less…
Scientists at the University of Stuttgart have developed an absorption chiller that is extremely compact, lightweight and stable in terms of operation, even at low evaporator temperatures and high heat rejection temperatures. Because of its compactness the absorption chiller has lower production costs and requires less refrigerant than conventional absorption chillers.
The invention discloses two chemical compound families derived from tetrahydrotriazine or coumarin selectively targeting the autophagic pathway.
The invention discloses methylation patterns found in umbilical cord blood which might be indicative towards an increased risk of afflictedness with an addiction.
The CRISPR technology could be the most im-portant new genetic engineering technique since the beginning of the biotechnology age in the 1970s. It was shown that it’s possible to use CRISPR to rid mice of muscular dystrophy, cure them of a rare liver disease, make human cells immune to HIV, and genetically modify monkeys. In addition there is interest in using CRISPR to gen-erate monkey models of diseases like autism, schizophrenia, Alzheimer’s disease, and bipolar disorder.
The present invention is a technology that significantly simplifies the measurement of BAT by PCR-based quantification of exosomal microRNA-92a in serum. Exosomal miR-92a levels inversely correlate with BAT activity. This novel method is as the first of its kind qualified to routinely measure the BAT activity in large cohorts of patients.
The measurement of BAT activity is not only important in the diagnosis and treatment of weight-related diseases, but is also a screening tool for the development of drugs that regulate the BAT activity. Such drugs are of use in pathological leanness (e.g. cachexia), obesity and other metabolic diseases.
The invention has been validated by studies in mice and man. On behalf of the University of Bonn, PROvendis offers access to rights for commercial use as well as the opportunity for further co-development. In case of interest we will be pleased to inform you about the patent status.